FINAL PROGRAM PROGRAMME FINAL - WWW.AMMI.CA - AMMI Canada
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
Where Canada’s Experts in Clinical Microbiology
and Infectious Diseases Will Meet VIRTUALLY!
FINAL PROGRAM
PROGRAMME FINAL
WWW.AMMI.CA WWW.CACMID.CA
April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
WELCOME
On behalf of the Association of Medical has also co-developed integrated symposia
Microbiology and Infectious Disease Canada and workshops for delegates to attend.
and the Canadian Association for Clinical Lastly, excellent Trainees’ Day interactive
Microbiology and Infectious Diseases we would sessions are planned with ample opportunity
like to welcome you to the 17th annual conjoint for networking.
meeting on the prevention, diagnosis, and We would like to acknowledge the generous
treatment of infectious diseases. We are and continued support from our industry
excited to be offering the event in a fully virtual partners, sponsors, and exhibitors, which has
format this year! From interactive scientific allowed us to preserve our high-quality meeting.
sessions to posters and an exhibit hall, this We encourage you to virtually walk through
will be an excellent opportunity to learn and the exhibit hall, expand your network, and
connect in an engaging online experience. see what’s new and exciting.
The Central and Scientific Planning Committees COVID-19 has put our professions at the
have put in long hours to produce an forefront, and we are excited to bring
exceptional virtual program for attendees together Canada’s experts in this unique
this year. There will be on-demand poster setting to not only highlight excellent COVID-19
sessions and live oral presentations to research, but also other hot topics in clinical
showcase the research done by our students, microbiology and infectious diseases.
residents, fellows, and colleagues, with awards
for the best student abstracts presented at AMMI Canada and CACMID are proud of the
the conference. The state-of-the-art clinical ongoing collaboration leading to this high-quality
lectures will cover up-to-date information on annual meeting. On behalf of the Central and
COVID-19 vaccines and immunity, the use of Scientific Planning Committees, we look forward
bacteriophages as antimicrobial therapies, to seeing you online and providing you with
zoonoses, and how artificial intelligence can not only an educational event, but also
be used to detect and control epidemics. opportunities for you to have fun, network,
The plenaries will focus on COVID-19, clinical and socialize with your colleagues.
controversies in infectious diseases and
Sarah Forgie
diagnostic microbiology, as well as hot topics
President, AMMI Canada
in infection control, diagnostic microbiology,
and both adult and paediatric infectious Tanis Dingle
diseases. The Scientific Planning Committee President, CACMID
Welcome | 2
April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
BIENVENUE
Au nom de l’Association pour la microbiologie également co-élaboré des symposiums et
médicale et l’infectiologie Canada et de ateliers intégrés pour les participants. Enfin, les
l’Association canadienne de microbiologie excellentes séances interactives de la Journée
clinique et des maladies infectieuses, nous des stagiaires constitueront d’excellences
vous souhaitons la bienvenue à la 17e occasions de réseautage.
conférence annuelle conjointe sur la prévention, Nous aimerions souligner le soutien
le diagnostic et le traitement des maladies généreux et continu de nos partenaires du
infectieuses. Nous sommes heureux de tenir secteur, de nos commanditaires et de nos
l’événement sous forme virtuelle cette année. exposants qui nous a permis de continuer à
À partir de séances scientifiques interactives offrir cette conférence de grand calibre. Nous
jusqu’aux présentations par affiches en passant vous encourageons à visiter le salon des
par la salle d’exposition, ce sera une excellente exposants, à élargir votre réseau et à découvrir
occasion de s’instruire et d’établir des liens ce qu’il y a de nouveau et d’intéressant.
dans une expérience en ligne engageante.
La COVID-19 a mis nos professions à
Les comités de planification générale et l’avant-garde et nous sommes heureux
scientifique ont consacré de longues heures à d’apporter des experts canadiens à cet
la mise au point d’un programme exceptionnel. événement unique non seulement pour mettre
Il y aura diverses présentations par affiches en évidence l’excellente recherche sur la
et orales d’études effectuées par nos étudiants, COVID-19 mais aussi d’autres sujets chauds en
résidents, boursiers et collègues, ainsi que la microbiologie clinique et maladies infectieuses.
remise de prix pour les meilleurs résumés
d’étudiants présentés à la conférence. Les L’AMMI Canada et la CACMID sont fières de
exposés cliniques de pointe donneront des cette collaboration continue qui conduit à
renseignements à jour sur les vaccins contre cette conférence de grande qualité. Au nom
la COVID-19 et l’immunité, l’utilisation de des comités de planification générale et
bactériophages comme traitments scientifique, nous vous recevrons avec plaisir
antimicrobiens, les zoonoses, et comment en ligne pour vous offrir non seulement un
l’intelligence artificielle peut servir à détecter événement éducatif, mais de nombreuses
et contrôler les épidémies. Les séances possibilités de vous distraire, de réseauter et
plénières porteront sur la COVID-19, les de socialiser avec vos collègues.
controverses cliniques dans les maladies
Sarah Forgie
infectieuses et la microbiologie diagnostique,
Présidente, AMMI Canada
ainsi que sur des sujets chauds dans le contrôle
de l’infection, la microbiologie diagnostique Tanis Dingle
et les maladies infectieuses chez les adultes Présidente, CACMID
et les enfants. Le Comité scientifique a
Bienvenue | 3
April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
COLLABORATING SOCIETIES
CONTENTS
Welcome 2
Bienvenue 3
How to Use the Virtual Platform 4
Collaborating Societies 5
Are You a Member? 6
COMMITTEES, AND COUNCILS
AMMI Canada Council 7
CACMID Board 7
Central Planning Committee (CPC) 7
Scientific Planning Committee (SPC) 8
Sponsorship Committee 8
Abstract Review Committee 8
Accreditation 9
CanMEDS 9
PROGRAM
Sunday, April 25 10
Monday, April 26 11
Tuesday, April 27 12
Canadian Society for Medical Laboratory Science
Wednesday, April 28 16
Société canadienne de science de laboratoire médical
Thursday, April 29 18
Friday, April 30 19
Poster and Oral Awards 20
Save the date! 21
Critical Care-Infectious Speaker Biographies 22
Diseases Network (CCIDN)
E-Posters 28
Student E-Posters 38
Author Index 44
Conflict of Interest Declarations 50
Industry co-developed presentations 53
UNACCREDITED PRESENTATIONS
Unaccredited Learning Activities 55
Exhibit Hall 60
Sponsors 61
General Information 61
Collaborating Societies | 4
April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
HOW TO USE THE
VIRTUAL PLATFORM
The 2021 AMMI Canada – CACMID Annual • Once you are registered, visit
Conference looks different this year. We will www.ammicanadacacmid2021.vfairs.com
be meeting virtually on the vFairs platform and login using the email address you
rather than in person. registered with
Tips to help you get started and to ensure • Once you are logged in, you will be brought
you have the best possible experience: into the 2021 annual conference lobby.
From the lobby you have access to and
• Chrome, Firefox and Safari are the best
are able to experience all the annual
browsers for video streaming the vFairs
conference has to offer:
platform. The platform does not
respond well to Explorer - 3 auditoriums that will host the
live and on demand (recorded)
• Downloading the most current version
dynamic program,
of Zoom will make the virtual experience
more optimal - 2 poster halls,
• Register: https://ammi-cacmid2021. - An interactive Exhibit Hall that
secure-registration.com/en/n7mb3v/event allows for 1:1 video interaction
with industry partners,
- Networking lounges so you can catch
up with friends and colleagues and,
- Gamification for those with a little
competitive nature in them.
• If you experience technical difficulties or
have any questions, stop by the Information
Desk in the lobby or email
ammicanadacacmid@getvfairs.io or
meetings@ammi.ca.
How to Use the Virtual Platform | 5
April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
OBJECTIVES
The AMMI Canada – CACMID Annual Conference short oral presentations, poster presentations
provides an interactive venue where experts and workshops. The Interactive Clinical
in the fields of diagnostic microbiology, Vignettes and the Incubator will be on hiatus
antimicrobial stewardship, infectious diseases, in 2021 and will return in 2022. The 2021
infection prevention and control, and public meeting will be a chance for attendees to
health meet. The conference attracts attendees showcase their research as well as get up
from across Canada and internationally. As in to speed with the latest in the areas of
previous years, the 2021 conference will provide microbiology, infection control, adult and
updates on a variety of topics to a diverse paediatric infectious diseases and related
audience of clinicians, microbiologists, subjects. Dynamic expert speakers will be
laboratory technologists, public health invited from across North America to ensure
professionals, infection prevention and control another exciting meeting.
practitioners, students and residents. The one In addition to the scientific component, the
difference this year is that the full conference meeting will provide ample opportunity for
will be virtual given COVID-19. attendees to network, exchange ideas, and
In addition to the pre-meeting Trainees’ Day, reconnect with colleagues all within the
the program will offer plenary sessions, state comfort of your own home or office!
of the art clinical lectures, integrated symposia,
ARE YOU A MEMBER?
To join AMMI Canada please contact: To join CACMID please contact:
Terence Wuerz, MD, MSc, FRCPC Ramzi Fattouh, PhD, FCCM
Secretary, AMMI Canada Secretary, CACMID
c/o AMMI Canada Secretariat c/o Laboratory Medicine
192 Bank Street St. Michael’s Hospital
Ottawa, ON K2P 1W8 30 Bond St., CC Rm 2-040
Toll-free: 1 (866) 467-1215 Toronto, ON M5B 1W8
Tel.: (613) 260-3233 ext. 103 Email: info@cacmid.ca
Fax: (613) 260-3235
For more information on CACMID visit:
Email: membership@ammi.ca
www.cacmid.ca
For more information on AMMI Canada visit:
www.ammi.ca
Objectives | 6
April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
AMMI Canada Council
President MM – Section Chair
Sarah Forgie, Edmonton, AB Philippe Lagacé-Wiens, Winnipeg, MB
President Elect ID – Section Chair
Deborah Yamamura, Hamilton, ON Shariq Haider, Hamilton, ON
Past President Members of Council
Todd Hatchette, Halifax, NS Isabelle Chiu, Edmonton, AB
Susy Hota, Toronto, ON
Treasurer Yves Longtin, Montréal, QC
Andrew Simor, Toronto, ON LeeAnne Luft, Kelowna, BC
Kelly MacDonald, Winnipeg, MB
Secretary
Karina Top, Halifax, NS
Terence Wuerz, Winnipeg, MB
CACMID Board
President Webmaster
Tanis Dingle, Edmonton, AB Vanessa Tran, Toronto, ON
Vice President Councillor
Agatha Jassem, Vancouver, BC Danielle Brabant-Kirwan, Sudbury, ON
Past President/Treasurer Councillor
Carmen Charlton, Edmonton, AB Esther Nagai, Toronto, ON
Secretary Councillor
Ramzi Fattouh, Toronto, ON Samir Patel, Toronto, ON
Meeting Secretary/Councillor Councillor
Chris Lowe, Vancouver, BC Valentina Russell, Winnipeg, MB
Scientific Planning Committee Councillor
Co-Chair Prameet Sheth, Kingston, ON
Rob Kozak, Toronto, ON
Central Planning Committee (CPC)
Co-Chairs Sponsorship Committee
Tanis Dingle Co-Chairs
Sarah Forgie Jeff Fuller
Shariq Haider
Scientific Planning
Committee Co-Chairs Abstract Co-Chairs
Robert Kozak Christian Lavallée
Susan Poutanen Christopher Lowe
Christine Turenne
Committee Members
Co-Treasurers Todd Hatchette
Carmen L. Charlton Agatha Jassem
Andrew Simor
Committees and Councils | 7
April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
Scientific Planning Committee (SPC)
Co-Chairs Philippe Lagacé-Wiens
Robert Kozak Christian Lavallée
Susan Poutanen Christopher Lowe
Christine Turenne Kathy Malejczyk
Esther Nagai
Committee Members Samir Patel
Danielle Brabant-Kirwan David Patrick
Marthe Charles Glenn Patriquin
William Connors Peter Pieroni
Melanie Di Quinzio Earl Rubin
Ramzi Fattouh Valentina Russell
Catherine Hogan Joanne Salmon
Agatha Jassem Yoko Schreiber
Jennie Johnstone Prameet M. Sheth
Farhan Khan Vanessa Tran
Sponsorship Committee
Co-Chairs Committee Members
Jeff Fuller Dwight Ferris
Shariq Haider Donald Vinh
Titus Wong
Deborah Yamamura
Abstract Review Committee
Co-Chairs Simon Grandjean-Lapierre
Christian Lavallée Daniel B. Gregson
Christopher Lowe David Harris
Catherine Hogan
Committee Members B. Lynn Johnston
Andrée-Anne Boisvert Imane Jroundi
Danielle Brabant-Kirwan Robert Kozak
Julie Carson Jérôme Laflamme
Vikas Chaubey Clayton MacDonald
Jeannette Comeau Nancy Matic
William Connors Vanessa Meier-Stephenson
Peter Daley Muhammad Morshed
Meghan Dey Esther Nagai
Tanis Dingle Conar O’Neil
Steven J. Drews Peter Pieroni
Eric Eckbo Prameet Sheth
Chelsey Ellis Christine Turenne
Ramzi Fattouh Bing Wang
Jeff Fuller Deborah Yamamura
Committees and Councils | 8
April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
ACCREDITATION
For specialists certified with the Royal College MOC credits to AMA PRA Category 1
of Physicians and Surgeons of Canada (RCPSC): Credits. Information on the process
The AMMI Canada - CACMID Annual Conference to convert Royal College MOC credits
is an Accredited Group Learning Activity to AMA credits can be found at
(Section 1) as defined by the Maintenance of www.ama-assn.org/go/internationalcme.
Certification Program of the Royal College of Please indicate your AMA ID Number
Physicians and Surgeons of Canada and when registering.
approved by AMMI Canada. You may claim
C. For Fellows and Specialists of the Canadian
a maximum of 20.75 hours.
College of Microbiologists and Diplomats
A. Mainport – Transfer of Hours of the American Board of Medical
Microbiology: The Canada College of
The Royal College of Physicians and
Microbiologists (CCM) accredits the AMMI
Surgeons of Canada allows for attendance
Canada – CACMID Annual Conference for
data of Section 1, Group Learning Activities
CE credits. Certificates of continuing
to be transferred directly into participants’
education activity are available through
MAINPORT Transfer of Hours. Please
the CCM for documentation of attendance
indicate your RCPSC ID Number when
and maintenance of certification. A one-hour
registering.
educational activity is equivalent to one
B. For specialists certified with the American CE credit. Program evaluation forms and
Medical Association (AMA): Through an record of CE activity can be obtained and
agreement between the Royal College of returned, once completed, by email to
Physicians and Surgeons of Canada and the FCCM co-chair (hadam@shared-
the American Medical Association, healthmb.ca) following the conference.
physicians may convert Royal College
The AMMI Canada Education Committee Chair, Dr. Joanne Salmon, is responsible for ensuring that
the AMMI Canada - CACMID Annual Conference is compliant with the Royal College National Standard
for Support of Accredited CPD Activities.
CANMEDS
CanMEDS is a framework that identifies and Collaborator CL
describes the abilities physicians require to Communicator CM
effectively meet the health care needs of the
people they serve. These abilities are grouped Health Advocate HA
thematically under seven roles. A competent Leader LE
physician seamlessly integrates the
Medical Expert ME
competencies of all seven CanMEDS
Roles. CanMEDs Roles have been identified Professional PR
for each Plenary and State of the Art (START) Scholar SC
Clinical Lecture using the following symbols:
(2021). Royal College of Physicians and Surgeons of Canada. CanMEDS Framework
Accreditation | 9
April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
PROGRAM
(all times indicated in Canadian Eastern time zone)
Sunday, April 25
On Demand Poster Viewing 13:45 – 14:15 Interactive Break Out Sessions
On Demand Exhibit Hall 14:15 – 14:25 Health Break
14:25 – 14:55 You can do this! Prepping for
12:00 – 16:30 Trainees’ Day
CL ME LE Exams in ID, Med Micro, and
Auditorium: Main Auditorium
SC PR Clin Micro
Moderator: Farhan Khan (Halifax, NS)
Speaker: Glenn Patriquin (Halifax, NS)
12:00 – 12:10 Welcome, Introductions
and Overview By the end of this session, participants should
12:10 – 12:40 It’s a Game of be able to:
CM CL LE Grantsmanship, and • Describe the formats of the final exam-
SC PR Your Ship Just Came In inations in Infectious Diseases, Medical
Speaker: Robert Kozak (Toronto, ON) Microbiology, and Clinical Microbiology
By the end of this session, participants should • Identify strategies and resources for
be able to: exam preparation
• Understand the current grant landscape and • Begin developing a study plan in
preparation for writing your exam
how to leverage your skills when applying
14:55 – 15:25 Interactive Break Out Sessions
• Learn my process for preparing for and
writing a grant 15:30 – 15:40 Wrap Up and Closing Remarks
• Appreciate the top 3 things I’ve learned 15:40 – 16:30 Trainees’ Day
from my grant successes and failures Networking Lounge
12:40 – 13:10 Interactive Break Out Sessions Following Trainees’ Day, you are invited to
join the Trainees’ Day Networking Lounge, to
13:15 – 13:45 Navigating the Real World
CM CL LE PR to Paradise Island!
meet, mingle and catch up virtually with
fellow trainees’, speakers and members of
Speaker: Yoko Schreiber (Sioux Lookout, ON) the AMMI Canada and CACMID boards.
By the end of this session, participants should
be able to:
• Recognize the many possible work
applications and opportunities
• Explore strategies to identify and land your
ideal job (including CVs and interviews)
• Acquire some personal tips for
creating balance
PROGRAM | Sunday, April 25 | 10April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
PROGRAM
(all times indicated in Canadian Eastern time zone)
Monday, April 26
On Demand Poster Viewing • Identify limitations in the use of randomized
On Demand Exhibit Hall controlled trials to compare seasonal
influenza vaccine efficacy
10:15 – 11:15 The Influenza Vaccine
HA ME SC (R)Evolution • Appreciate the need for real-world data
related to influenza vaccines
Auditorium: Co-Developed Presentations This educational event is an Accredited Group Learning
Moderator: Philippe Lagacé-Wiens Activity (Section 1) as defined by the Maintenance of
Certification program of the Royal College of Physicians
(Winnipeg, MB)
and Surgeons of Canada and approved by AMMI Canada.
Speaker: Matthew Miller (Hamilton, ON)
The program was co-developed with AMMI Canada
By the end of the session the participants and Seqirus and was planned to achieve scientific
will be able to: integrity, objectivity and balance.
• Outline the main factors that impact 11:15 – 11:30 Break
annual influenza vaccine effectiveness
11:30 – 14:00 Plenary: COVID-19 – What We Know, What We Don’t Know
Auditorium: Main Auditorium
Moderators: Robert Kozak (Toronto, ON)
• Illustrate the usefulness of rapid sequencing
in the response to COVID-19
Susan Poutanen (Toronto, ON)
12:35 – 13:05 What’s Hot in Transmission/
11:30 – 11:35 Welcome Remarks and ME CM CL LE Public Health/Infection Control
Introduction
SC
11:35 – 11:55 Where Have We Been and
Speaker: Dominik Mertz (Hamilton, ON)
ME CL LE SC Where Are We Going? –
Lessons Learned from a By the end of this session, participants should
National Perspective be able to:
Speaker: Theresa Tam (Ottawa, ON) • Review the science regarding
By the end of this session, participants should SARS-CoV-2 transmission
be able to: • Discuss the science regarding SARS-CoV-2
• Summarize where we have been and infection control and public health measures
where we are going regarding the • Recognize the challenges of balancing
national response to COVID-19 infection control and public health
• Define lessons learned from Canada’s guidance and buy-in from health care
workers and the public
response to date
13:10 – 13:40 What’s Hot in Treatment
• Describe Canada’s approach to domestic
ME CM CL LE SC
manufacturing of vaccines and personal
protective equipment Speaker: Srinivas Murthy (Vancouver, BC)
12:00 – 12:30 What’s Hot in Diagnostics, By the end of this session, participants should
ME CL LE SC Genomics, and Serology
be able to:
Speaker: Mel Krajden (Vancouver, BC) • Review the evidence behind COVID-19
By the end of this session, participants should treatment options
be able to: • Describe the Canadian arm of the WHO’s
• Summarize COVID-19 diagnostic tools: Solidarity Therapeutics Trial
NAT and antigen detection, genomics, • Discuss the challenges of navigating
and serology treatment guidance in light of politics,
• Define optimal use cases and press releases, social media, and pre-peer
review manuscripts
specimen types for different COVID-19
diagnostic modalities 13:40 – 14:00 Panel Question and Answer
PROGRAM | Monday, April 26 | 11April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
PROGRAM
(all times indicated in Canadian Eastern time zone)
Monday, April 26
14:00 – 14:15 Health Break • Describe Canada’s approach to COVID-19
vaccine approval, priority group
14:15 – 15:15 determination, administration, and
State of the Art (START) lessons learned from regional and
Clinical Lecture international approaches
ME CL LE SC What’s Hot in COVID-19:
• Describe the impact of variants of concern
Vaccines and Immunity and expected vaccine effectiveness
Auditorium: Main Auditorium
16:00 – 18:00 Live Interaction
Moderators: Robert Kozak (Toronto, ON)
Poster Presenters at Posters
Susan Poutanen (Toronto, ON)
Location: Poster Hall
Speaker: Joanne Langley (Halifax, NS)
16:00 – 18:00 Live Interaction
By the end of this session, participants should
Exhibitors at Exhibit Booths
be able to:
Location: Exhibit Hall
• Review the effectiveness and adverse
events associated with different
COVID-19 vaccines
Tuesday, April 27
On Demand Poster Viewing
On Demand Exhibit Hall
11:30 – 14:00
Plenary: Tuberculosis Update • Spark insight on ways in which integrative
Auditorium: Main Auditorium knowledge translation between Indigenous
Moderators: Earl Rubin (Montréal, QC) wellness systems and conventional TB
Yoko Schreiber (Sioux Lookout, ON) interventions increase TB program efficacy
11:30 – 12:10 Morphology, Resistance 12:10 – 12:45 Advances in TB Diagnostics
ME CM CL HA and Decolonizing TB ME CM CL SC
SC PR Speaker: Marcel Behr (Montréal, QC)
Speaker: Kathleen McMullin By the end of this session, participants should
(Prince Albert, SK)
be able to:
By the end of this session, participants should
be able to: • Compare the advantages and limitations of
nucleic acid amplification to diagnose TB
• Increase awareness of the roots of TB
• Discuss how whole genome sequencing
inequities for Indigenous Peoples of
is being applied to the diagnosis of TB
Canada within a socio-historic and
structural perspective • Appreciate how all new methods require
appropriate laboratory controls
• Promote identification of concrete
actions furthering Indigenous
self-determination and why it is
case-critical for mitigating disproportionate
suffering associated with TB
PROGRAM | Tuesday, April 27 | 12April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
PROGRAM
(all times indicated in Canadian Eastern time zone)
Tuesday, April 27
12:45 – 13:25 Treatment of latent TB. 14:00 – 14:30 Health Break
ME CL LE SC Recent advances in new
14:30 – 15:45 Oral Presentations –
shorter regimens, and new Sessions A
recommendations – by the Auditorium: Main Auditorium
World Health Organization,
Moderator: Jennifer Tam (Vancouver, BC)
and the Centres for
Disease Control A01
Speaker: Dick Menzies (Montréal, QC) Incidence and timing of prosthetic joint
infections following primary and revision
By the end of this session, participants should
arthroplasty: a population-based
be able to: retrospective cohort study
• Understand the advantages of the new C Kandel1, N Daneman2, J Widdifield3,4,5,
BE Hansen6, R Jenkinson7,8, A McGeer9
shorter Latent TB treat regimens compared
to the previously recommended treatment
1
University of Toronto, Toronto, ON; 2Sunnybrook Health
Sciences Centre, Toronto, ON; 3Sunnybrook Research
with 9 months Isoniazid (9INH) Institute, Holland Bone & Joint Program, Toronto, ON;
• Institute of Health Policy, Management and Evaluation,
4
Weigh the relative benefits and risk of University of Toronto, Toronto, ON; 5ICES, Toronto, ON;
three alternative short latent TB treatment 6
Division of Gastroenterology, Toronto General Hospital,
regimens – be better informed about University Health Network, Toronto, ON; 7Division of
Orthopaedic Surgery, Department of Surgery, University
which regimen would be best suited to
of Toronto, Toronto, ON; 8Division of Orthopaedic Surgery,
which types of patients Sunnybrook Health Sciences Centre, Toronto, ON;
9
Sinai Health System, Toronto, ON
• Review the latest recommendations
for treatment of latent TB from two A02
authoritative agencies – the World Clinical characteristics, management, and
Health Organization, and the Centres outcomes of patients with indeterminate
for Disease Control (US) Clostridioides difficile tests using a modified
2-step algorithm
13:25 – 14:00 Tuberculosis from birth LE Burnes1, SW Smith1,2,
ME CL LE SC to adolescence K Kowalewska-Grochowska1,3, JZ Chen1,2
Speaker: Ian Kitai (Toronto, ON) 1
University of Alberta, Edmonton, AB; 2University of
Alberta Hospital, Edmonton, AB; 3Provincial Laboratory
By the end of this session, participants should of Public Health (Microbiology), Edmonton, AB
be able to:
A03
• Recognize the common clinical presentation
Urinary tract infection investigation and
of TB at different ages treatment in older adults presenting to the
emergency department with confusion - A
• Understand the epidemiology of paediatric
health record review of local practice patterns
TB in Canada and the world including
RAM Pinnell1, T Ramsay2, HX Wong3, P Joo2,3
gaps in knowledge 1
Department of Medicine, University of Ottawa, Ottawa, ON;
• Recognize the unique vulnerability of
2
3
Ottawa Hospital Research Institute, Ottawa, ON;
Department of Family Medicine, University of Ottawa,
young infants to TB disease and the Ottawa, ON
management of the infant born to a
mother who has TB disease
PROGRAM | Tuesday, April 27 | 13April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
PROGRAM
(all times indicated in Canadian Eastern time zone)
Tuesday, April 27
A04 B03
Impact of Cobas® PCR Media freezing on Evaluation of isavuconazole gradient
SARS-CoV-2 viral RNA integrity and whole strips for susceptibility testing of
genome sequencing analyses Mucorales isolates
P Benoit1, F Point2, S Gagnon3, D Kaufmann1,2,3, L Feng1, L Turnbull2, B Jansen2, TC Dingle1,2
C Tremblay1,2,3, RP Harrigan4, I Hardy1,2,3, 1
University of Alberta, Edmonton, AB; 2Alberta Precision
F Coutlée1,2,3, S Grandjean-Lapierre1,2,3 Laboratories, Edmonton, AB
1
Université de Montréal, Montréal, QC; 2Centre de
Recherche du Centre Hospitalier de l’Université de B04
Montréal, Montréal, QC; 3Centre Hospitalier de l’Universi- Evaluation of whole genome sequencing-
té de Montréal, Montréal, QC; 4University of British based subtyping methods for the surveillance
Columbia, Vancouver, BC
of Shigella flexneri and Shigella sonnei and
14:30 – 15:45 Oral Presentations – the confounding effect of mobile genetic
Sessions B elements in propagated outbreaks
I Bernaquez1, C Gaudreau2,3, PA Pilon4,5,
Auditorium: Main Auditorium
F Doualla-Bell1, D Roy1, S Bekal1,3
Moderator: Peter Daley (St. John’s, NL) 1
Laboratoire de santé publique du Québec, Sainte-Anne-
de-Bellevue, QC; 2Microbiologie médicale et infectiologie,
B01
Centre Hospitalier de l’Université de Montréal (CHUM),
Verification of the New bioMérieux Montréal, QC; 3Département de microbiologie, infectiologie
Piperacillin/Tazobactam E-Test® against et immunologie, Université de Montréal, Montréal, QC;
reference broth microdilution
4
Direction régionale de santé publique, Centre intégré
universitaire de santé et de services sociaux du Centre-
P Lagacé-Wiens1,2, HJ Adam1,2, C Turenne1,2,
Sud-de-l’île-de-Montréal, Montréal, QC; 5Département de
M Stein1,2, A Walkty1,2, JA Karlowsky1,2 médecine sociale et préventive, Université de Montréal,
1
Shared Health, Winnipeg, MB; 2University of Manitoba, Montréal, QC
Winnipeg, MB
17:30 – 19:30 Merit and Association Awards
B02 Masters of Ceremony:
Performance of matrix-assisted laser Sarah Forgie, AMMI Canada President
desorption/ionization time of flight mass Tanis Dingle, CACMID President
spectrometry for identification of Curtis Cooper, CFID President
filamentous molds using several different Auditorium: Unaccredited Presentations
extraction methods
L Li1,2, E Bryce1,2, B Velapatino2, R Najafi3, Following the Awards Ceremony, you are
L Kishi3, B Wang4, C Swanston4, L Hoang2,5, invited to join the Awards Chatroom
V Tang3, M Charles1,2 (located inside the Friendly Chat Networking
1
Division of Medical Microbiology and Infection Prevention Lounge) to virtually meet and congratulate
and Control, Vancouver General Hospital, Vancouver, the recipients and mingle and catch up
BC; 2Pathology and Laboratory Medicine, University of
British Columbia, Vancouver, BC; 3Provincial Health with fellow attendees.
Services Authority, Vancouver, BC; 4Division of Medical
Microbiology, Kelowna General Hospital, Kelowna, BC;
5
BC Centre for Disease Control, Vancouver, BC
PROGRAM | Tuesday, April 27 | 14April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
Tuesday, April 27 CANADIAN ASSOCIATION
17:30 – 19:30 OF CLINICAL MICROBIOLOGY
Masters of Ceremony:
AND INFECTIOUS
Sarah Forgie, AMMI Canada President
Tanis Dingle, CACMID President
DISEASES AWARDS
Curtis Cooper, CFID President John G. FitzGerald – CACMID Out-
Auditorium: Unaccredited Presentations standing Microbiologist Award
2020 – Michael Mulvey
ASSOCIATION OF MEDICAL 2021 – Allison McGeer
MICROBIOLOGY AND
INFECTIOUS DISEASE bioMérieux Award for Leadership
CANADA AWARDS in Syndromic Infectious Disease
Testing Award
AMMI Canada Distinguished 2021 – Marek Smieja
Service Award
2019 – Daniel Gregson CANADIAN FOUNDATION
AMMI Canada Lifetime FOR INFECTIOUS
Achievement Award DISEASES AWARDS
2019 – Jay Keystone
Dr. John M. Embil Mentorship Award
AMMI Canada Young Investigator
2020 – Marcel Behr
Award
2021 – Todd Lee
2019 – Manish Sadarangani
2020 – Matthew Cheng Dr. Juan A. Embil Award of Excellence
in Infectious Diseases Research
AMMI Canada Trainee Research
2020 – Alexander Lawandi
Award
2021 – Georges Ambaraghassi
2019 – Samuel Chorlton
2020 – Alice Zhabokritsky CFID Undergraduate Summer
Research Grant
JAMMI Trainee Scientific Article Award
2020 - Jonathan Chung and Leslie Fell
2020 – Brittany Kula
2021 - Amaanat Gill and Sayed Zain Ahmad
AMMI Canada / bioMérieux
AMMI Canada Medical Student
Post Residency Fellowship in
Research Awards
Microbial Diagnostic
2020 – E
mma Finlayson-Trick and
2020 – Jonathon Kotwa
Marissa Nahirney
AMMI Canada – CFID Medical
Student Research Award
2021 – Vinyas Harish
altona Diagnostics Canada Medical
Student Research Award
2020 - Siena Davis
2021 - Sonia Igboanugo
Following the Awards Ceremony, you are invited to join the Awards
Chatroom (located inside the Friendly Chat Networking Lounge) to
virtually meet and congratulate the recipients and mingle and catch up
with fellow attendees.
PROGRAM | Tuesday, April 27 | 15April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
PROGRAM
(all times indicated in Canadian Eastern time zone)
Wednesday, April 28
On Demand Poster Viewing 13:15 – 14:15
On Demand Exhibit Hall State of the Art (START)
11:00 – 12:00 S
trategic Deployment of Clinical Lecture
ME CL HA SC COVID-19 Treatment Options:
ME CL LE Use of Artificial Intelligence to
Who, What, Where and How? HA SC Detect and Control Epidemics
Auditorium: Co-developed Presentations Auditorium: Main Auditorium
Moderators: William Connors (Vancouver, BC) Moderator: Prameet Sheth (Kingston, ON)
Marthe Charles (Vancouver, BC) Speaker: Kamran Khan (Toronto, ON)
Speakers: Lynora Saxinger (Edmonton, AB) By the end of this session, participants should
Emily McDonald (Montreal, QC) be able to:
Zain Chagla (Hamilton, ON) • Describe a high-level overview of big
By the end of the session the participants will data and machine learning
be able to: • Discuss potential applications of
machine learning in microbiology
• Review risk factors for development and
& infectious diseases
progression of COVID-19 and the impact
of vaccination • Demonstrate how machine learning and
natural language processing have been
• Implement the use of therapeutics in
used to build a global epidemic early
outpatients with COVID-19, including
how to deploy them and to whom warning system
14:15 – 14:30 Health Break
• Discuss the strategic use of therapeutics
in inpatients with COVID-19 14:30 – 15:45 Oral Presentations –
Sessions C
This educational event is an Accredited Group Learning Auditorium: Main Auditorium
Activity (Section 1) as defined by the Maintenance of Moderator: Susy Hota (Toronto, ON)
Certification program of the Royal College of Physicians
and Surgeons of Canada and approved by AMMI Canada. C01
The program was co-developed with AMMI Canada
and Gilead and was planned to achieve scientific Children hospitalized with community-
integrity, objectivity and balance. acquired pneumonia complicated by
effusion: A single-centre, retrospective
12:00 – 13:00 cohort study
G Alemayheu, CSJ Lee, JM Pernica
State of the Art (START)
McMaster University, Hamilton, ON
Clinical Lecture
Bacteriophages – Solution to C02
ME CL SC
Antimicrobial Resistance? Highest prevalence of Mycoplasma genitalium
Auditorium: Main Auditorium infection among other sexually transmitted
Moderator: William Connors (Vancouver, BC) diseases and macrolide and fluoroquinolone
resistance mediating mutations:
Speaker: Steffanie Strathdee (San Diego, CA) A Saskatchewan perspective
By the end of this session, participants should NR Parmar1,2, L Mushanski3, T Wanlin2,
be able to: A Lepe1,2, A Lang3, J Minion3, JR Dillon1,2
1
University of Saskatchewan, SK; 2Vaccine and Infectious
• Understand the biology behind Disease Organization, SK; 3Saskatchewan Health
phage therapy Authority, Roy Romanow Provincial Laboratory, SK
• Appreciate the complexities of
phages and phage therapy
• Predict how phage therapy can fail
13:00 – 13:15 Health Break
PROGRAM | Wednesday, April 28 | 16April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
PROGRAM
(all times indicated in Canadian Eastern time zone)
Wednesday, April 28
C03 D02
Population level compliance with provincial Molecular and epidemiological
treatment guidelines for the management characterization of Adult Healthcare (HA)
of gonorrhea in Alberta, Canada, 2000-2019 and Community-Associated (CA) Clostridioides
A Ugarte Torres1, C Diaz Pallarez2, J Niruban3, difficile infections 2015-2019, Canada
P Smyczek3, D Strong4, J Gratrix3, AE Singh5 T Du1, K Baekyung Choi2, R Hizon1, A Silva2,
1
Division of Infectious Diseases, University of Calgary, L Pelude2, J Brooks2,3, GN Al-Rawahi4, JC Collet4,
Calgary, AB; 2Department of Medicine, University of B Chow5, JL Comeau6, I Davis7, GA Evans8,
Calgary, Calgary, AB; 3STI Centralized Services, Alberta C Frenette9, G Han10, SS Hota11, J Johnstone12,
Health Services, Edmonton, AB; 4Department of Community KC Katz13, P Kibsey14, J Langley6, BE Lee15,
Health Services, University of Calgary, Calgary, AB;
5
Division of Infectious Diseases, University of Alberta, Y Longtin16, D Mertz17, J Minion18, M Science19,
Edmonton, AB J Srigley4, P Stagg20, KN Suh3, N Thampi21,
AHM Wong22, on behalf of the Canadian Nosocomial
C04 Infection Surveillance Program (CNISP)
Cerebrospinal fluid shunt infections in 1
National Microbiology Laboratory, Winnipeg, MB;
children: a descriptive cohort study of 2
Public Health Agency Canada, Ottawa, ON; 3The Ottawa
Canadian and US patients 2013-2019 Hospital, Ottawa, ON; 4BC Children’s Hospital and BC
Women’s Hospital & Health Centre, Vancouver, BC;
A McAlpine1, M Barton2, A Balamohan3, 5
Alberta Health Services, Calgary, AB; 6IWK Health Centre,
HD Davies4, G Skar4, MA Lefebvre5, D Freire6, Halifax, NS; 7QEII Health Sciences Centre, Halifax, NS;
NMA Le Saux7, J Bowes8, JA Srigley1, P Passarelli9, 8
Kingston General Hospital, Kingston, ON; 9McGill University
J Bradley9, S Khan10, R Purewal11, I Viel-Thériault12, Health Centre, Montréal, QC; 10Provincial Health Services
A Ranger2, JL Robinson13 Authority, Vancouver, BC; 11University Health Network,
Toronto, ON; 12Sinai Health System, Toronto, ON; 13North
1
BC Children’s Hospital, Vancouver, BC; 2Victoria York General Hospital, Toronto, ON; 14Royal Jubilee
Hospital, London, ON; 3Arkansas Children’s Hospital, Hospital, Victoria, BC; 15Stollery Children’s Hospital,
Little Rock, Arkansas, USA; 4University of Nebraska, Edmonton, AB; 16SMBD-Jewish General Hospital,
Omaha, Nebraska, USA; 5Montréal Children’s Hospital, Montréal, QC; 17McMaster University and Hamilton
Montréal, QC; 6University of Alberta, Alberta, AB; Health Sciences, Hamilton, ON; 18Regina General
7
University of Ottawa, Ottawa, ON; 8Children’s Hospital Hospital, Regina, SK; 19Hospital for Sick Children,
of Eastern Ontario, Ottawa, ON; 9Rady Children’s Toronto, ON; 20Western Memorial Hospital, Corner
Hospital, San Diego, California, USA; 10McMaster Brook, NL; 21Children’s Hospital of Eastern Ontario,
Children’s Hospital, Hamilton, ON; 11Jim Pattison Ottawa, ON; 22Royal University Hospital, Saskatoon, SK
Children’s Hospital, Saskatoon, SK; 12CHU de Québec,
Québec City, QC; 13University of Alberta, Edmonton, AB D03
14:30 – 15:45 Oral Presentations – Optimizing the treatment of Staphylococcus
Sessions D aureus bloodstream infection with the
Auditorium: Main Auditorium implementation of a molecular assay and
antimicrobial stewardship intervention
Moderator: Muhammad Morshed
(Vancouver, BC) Hilal Al Sidairi1,2, EK Reid3, N Sandila4,
J LeBlanc2,3, I Davis2,3, PE Bonnar2,3
D01 Ibri Referral Hospital, Ministry of Health, Ibri, Oman;
1
Impact of antibiotic prescribing feedback Dalhousie University, Halifax, NS; 3Nova Scotia Health,
2
Halifax, NS; 4Research Methods Unit, Nova Scotia Health,
to high volume primary care physicians: Halifax, NS
A randomized controlled trial
KL Schwartz1,2,3, N Ivers4, BJ Langford1, D04
M Taljaard5, D Neish6, KA Brown1, V Leung1,
Assessment of empirical vancomycin use
N Daneman7, J Alloo8, M Silverman9, E Shing1, and appropriateness at a tertiary care
J Grimshaw5, JA Leis7, JHC Wu1, G Garber1 pediatric hospital
1
Public Health Ontario, Toronto, ON; 2Dalla Lana School K Alsager1, J Vayalumkal2, C Constantinescu3
of Public Health, University of Toronto, Toronto, ON;
3
Unity Health Toronto, Toronto, ON; 4Women’s College
1
Pediatric Antimicrobial Stewardship Fellow, University
Hospital, Toronto, ON; 5Ottawa Hospital Research Institute, of Calgary, Calgary, AB; 2Section of Infectious Diseases,
Toronto, ON; 6IQVIA, Montréal, QC 7Sunnybrook Research Department of Pediatrics, University of Calgary, Calgary,
Institute, Toronto, ON; 8Ontario Medical Association, AB; 3Pediatric Infectious Disease, Clinical Assistant
Toronto, ON; 9London Health Sciences Centre, Toronto, ON Professor, University of Calgary, Calgary, AB
15:45 – 18:00 Live Interaction Poster Presenters at Posters
Location: Poster Hall
15:45 – 18:00 Live Interaction Exhibitors at Exhibit Booths
Location: Exhibit Hall
PROGRAM | Wednesday, April 28 | 17April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
PROGRAM
(all times indicated in Canadian Eastern time zone)
Thursday, April 29
On Demand Poster Viewing 13:30 - 15:00 Live Interaction
On Demand Exhibit Hall Exhibitors at Exhibit Booths
Location: Exhibit Hall
11:30 – 13:30
15:00 – 16:15 Oral Presentations –
Plenary: Clinical Controversies
Session E
Auditorium: Main Auditorium
Auditorium: Main Auditorium
Moderators: Titus Wong (Vancouver, BC)
Moderator: Vanessa Tran (Toronto, ON)
Manish Sadarangani
(Vancouver, BC) E01
11:30 – 12:30 Mandatory Childhood Waning anti-nucleocapsid IgG signal
ME CM CL LE Immunization: Should We among SARS-CoV-2 seropositive blood
Debate This or Consider donors: May- November 2020
HA SC PR
Our Options? S Saeed1, SJ Drews2,3, C Pambrun4, SF O’Brien1
(co-developed by CAIRE: Canadian Association for 1
Canadian Blood Services, Epidemiology and Surveillance,
Immunization, Research, Evaluation and Research) Ottawa, ON; 2Canadian Blood Services, Microbiology,
Speakers: Noni MacDonald (Halifax, NS) Edmonton, AB; 3University of Alberta, Department of
Laboratory Medicine and Pathology, Edmonton, AB;
Monika Naus (Vancouver, BC) 4
Canadian Blood Services, Medical Affairs and Innovation,
Ottawa, ON
By the end of this session, participants should
be able to: E02
• Review the concepts related to mandatory SARS-CoV-2 Serology: Validation of
childhood immunization high-throughput Chemoluminescent
Immunassay (CLIA) platforms and a
• Describe the impact of COVID-19 on
field study in British Columbia
uptake of childhood immunization and AS Mak1, I Sekirov1, D Cook1, P Levett1,
its potential implications and solutions, A Jassem1, MG Morshed1, A Olmstead1,
including the role of ‘mandatory’ models V Barakauskas2, J Simons3, S Masood4,
12:30 – 13:30 To Screen or Not to Screen: M Charles5, A Hayden6, M Krajden1
ME CM CL LE VRE-Evaluating the Data BC Center for Disease Control, Vancouver, BC 2Children’s
1
and Women’s Hospital, Vancouver, BC; 3St. Paul’s Hospital,
Debaters: Jennie Johnstone (Toronto, ON)
Providence Health, Vancouver, BC;4Surrey Memorial
– For hospital IPAC programs Hospital, Surrey, BC; 5Vancouver General Hospital,
screening for VRE Vancouver, BC; 6Vancouver Coastal Health Authority,
Vancouver, BC
Stephanie Smith (Edmonton, AB)
– Against hospital IPAC
programs screening for VRE
Resolution: Be it resolved that hospital
Infection Prevention and
Control programs should no
longer screen for VRE
By the end of this session, participants should
be able to:
• Define the clinical impact of VRE infection
and understand the changing clinical
epidemiology of VRE in Canadian hospitals
• Discuss the evidence for and against VRE
control programs
• Recognize the gaps in knowledge around
VRE prevention and control
PROGRAM | Thursday, April 29 | 18April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
PROGRAM
(all times indicated in Canadian Eastern time zone)
Thursday, April 29
E03 E04
Analysis of the performance of water Saliva assay for viral examination of
gargle samples for SARS-CoV-2 detection SARS-CoV-2 (SAVE-CoV): A pilot study
using heat extraction followed by SM Poutanen1,2, C Lemieux2,3, B Hazlett1,
laboratory-developed nucleic acid M Landes2,3, A McGeer1,2, TT Mazzulli1,2,
amplification testing S Friedman2,3
S Gobeille Paré1, J Bestman-Smith1, J Fafard2, University Health Network/Sinai Health System, Toronto,
1
F Doualla-Bell2, M Jacob-Wagner1, M St-Hilaire3, ON; 2University of Toronto, Toronto, ON; 3University
S Beauchemin3, V Boucher4, F Vancol-Fable3, Health Network, Toronto, ON
C Lavallée3, AC Labbé3,5,6
16:15 - 18:00 Live Interaction
1
Centre Hospitalier Universitaire de Québec - Université
Laval, Québec, QC ;2Laboratoire de Santé Publique du Poster Presenters at Posters
Québec, Institut National de Santé Publique du Québec, Location: Poster Hall
Sainte-Anne-de-Bellevue, QC 3CIUSSS de l’Est-de-l’Ile-de-
Montréal, Montréal, QC; 4Centre Hospitalier Universitaire
de Québec - Université Laval Research Center, Québec,
QC; 5Centre Hospitalier Universitaire de Montréal,
Montréal, QC 6Université de Montréal, Montréal, QC
Friday, April 30
10:00 - 12:00 Live Interaction By the end of this session, participants should
Poster Presenters at Posters be able to:
Location: Poster Hall • Discuss the drivers of emerging zoonotic
10:00 - 12:00 Live Interaction infections, how they are being affected in
Exhibitors at Exhibit Booths the Anthropocene and their implications
for future research and knowledge
Location: Exhibit Hall
mobilization.
12:30 – 13:30 • Propose a 5-step pathway to rising to the
State of the Art (START) challenges of emerging zoonoses in these
Clinical Lecture times of unprecedented change and
accelerating exceptions to prevent the
ME CM CL HA Zoonoses and Preparedness next pandemic
in the Anthropocene
Auditorium: Main Auditorium 13:30 – 13:45 Health Break
Moderator: Robert Kozak (Toronto, ON)
Speaker: Craig Stephen (Nanoose Bay, BC)
PROGRAM | Friday, April 30 | 19April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
PROGRAM
(all times indicated in Canadian Eastern time zone)
Friday, April 30
13:45 – 15:45 14:45 – 15:15 What’s Hot in Diagnostic
Plenary: What’s Hot in Adult and ME CM Microbiology
Paediatric Infectious Diseases, Speaker: David Goldfarb (Vancouver, BC)
Infection Control and Diagnostic By the end of this session, participants should
Microbiology? be able to:
(co-developed by CFID: Canadian Foundation for
Infectious Diseases) • Describe recent new findings that impact
Auditorium: Main Auditorium the practice of diagnostics microbiology
Moderators: Shariq Haider (Hamilton, ON) 15:15 – 15:45 What’s Hot in Infection
David Patrick (Vancouver, BC) ME CM Prevention and Control (IPAC)
13:45 – 14:15 What’s Hot in Adult Speaker: Titus Wong (Vancouver, BC)
ME CM Infectious Disease By the end of this session, participants should
Speaker: Natasha Press (Vancouver, BC) be able to:
By the end of this session, participants should • Describe recent new findings that
be able to: impact the practice of infection
• Describe recent new findings that impact prevention and control
the practice of adult infectious diseases
14:15 – 14:45 What’s Hot in Paediatric 15:45 – 16:00 Closing Remarks and Student
ME CM CL Infectious Disease Awards Presentations
Speaker: Joan Robinson (Edmonton, AB) Auditorium: Main Auditorium
Speakers: Tanis Dingle (Edmonton, AB)
By the end of this session, participants should Sarah Forgie (Edmonton, AB)
be able to:
• Describe recent new findings that
impact the practice of paediatric
infectious diseases
POSTER AND ORAL
AWARDS
Association of Medical Microbiology and Canadian Association for Clinical
Infectious Disease (AMMI) Canada Poster Microbiology and Infectious Diseases
Award (CACMID) Technologist Poster Award
Canadian Association for Clinical Canadian College of Microbiologists (CCM)
Microbiology and Infectious Diseases Poster Award
(CACMID) Student Oral Presentation Canadian College of Microbiologists (CCM)
Award Dr. Kenneth Rozee Memorial Poster Award
Canadian Association for Clinical Dr. Susan King Paediatric Abstract Award
Microbiology and Infectious Diseases
(CACMID) Poster Award
PROGRAM | Friday, April 30 | 20April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
Vancouver
April 6 – 9, 2022
Save the date!
Vancouver 2022 | 21April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
SPEAKER BIOGRAPHIES
MARCEL BEHR DAVID GOLDFARB
Marcel Behr is a clinician-scientist with David Goldfarb MD FRCPC is a Clinical
appointments of Full Professor in the Department Associate Professor in the Department of
of Medicine and Associate member in the Pathology and Laboratory Medicine at
departments of Epidemiology and Biostatistics University of British Columbia and Medical
as well as Microbiology and Immunology. Microbiologist and Pediatric Infectious
He was the founding Director of the McGill Disease Physician at BC Children’s Hospital.
International TB Centre and led it from 2012 His research focuses on novel diagnostic,
to 2018. He is the Associate Program Leader prevention, and management strategies for
of the Infectious Diseases and Immunity in childhood infectious diseases particularly in
Global Health Program at the Research remote and resource limited settings. He
Institute of the McGill University Health leads several research projects in sites in
Centre since 2016 and in 2017 he became Africa and northern Canada.
the co-Director the McGill Interdisciplinary
JENNIE JOHNSTONE
Initiative in Infection and Immunity (McGill-i4).
Jennie Johnstone obtained her medical degree
He is the interim director of McGill Infectious
from Dalhousie University. She then moved
Diseases Division. Dr. Behr trained at the
to Edmonton, Alberta where she completed
University of Toronto, Queen’s, McGill and
her Internal Medicine and Infectious Disease
Stanford. His work has been recognized by
training at the University of Alberta. Following
election into the Canadian Academy of Health
her residency, she completed a clinical research
Sciences, the Royal Society of Canada, the
fellowship in Edmonton. She moved to Hamilton
American Society for Clinical Investigation
in July 2008 where she practiced Infectious
and the American Academy of Microbiology.
Diseases at McMaster University and completed
Dr. Behr’s lab uses bacterial genomic
her PhD in Health Research Methodology
methodologies to study the epidemiology
(Epidemiology). Following her PhD, she joined
and pathogenesis of tuberculosis and other
Public Health Ontario as an Infection Prevention
mycobacterial diseases.
and Control physician where she continues to
ZAIN CHAGLA lead research focused on Infection Prevention
Zain Chagla is an M.D. specializing in internal and Control in the areas of vancomycin resistant
medicine, tropical medicine, and infectious enterococci, ventilator associated pneumonia
diseases, he is Medical Director, Infection and Clostridium difficile. She worked at
Control, at St. Joseph’s Hospital and Hamilton St. Joseph’s Health Center in Toronto for 5 years,
Health Sciences, Niagara Health, and is a where she practiced Infectious Diseases and
consultant at Woodstock General Hospital. ran the Infection Prevention and Control
He is an associate Professor of Medicine at program. In 2018 she left St. Joseph’s to
McMaster University, and adjunct faculty at become a physician co-lead of Infection
the University of Namibia in the Department Prevention and Control at Sinai Health
System in Toronto where she is also an
of Medicine. He also received his M.Sc from
Assistant Professor in the Laboratory Medicine
the London School of Hygiene and Tropical
and Pathobiology and Dalla Lana School of
Medicine, and a Diploma in Tropical Medicine
Public Health, University of Toronto.
completed in Tanzania and Uganda through
the London School of Hygiene and Tropical
Medicine. Dr. Chagla has been a part of
COVID-19 clinical trials, infection control and
testing, and epidemiology.
Speaker Biographies | 22April 25–30 / 25–30 avril
April 25–30 / 25–30 avril
KAMRAN KHAN and Zika virus. He also serves on the boards
Kamran Khan is an infectious disease of the Canadian College of Microbiologists
physician-scientist and a Professor of Medicine and the Canadian Association of Clinical
and Public Health at the University of Toronto. Microbiology and Infectious Diseases.
Motivated by his experiences as a frontline Currently he works as a clinical microbiologist
healthcare worker during the 2003 Toronto at Shared Hospital Laboratory at Sunnybrook
SARS outbreak, Dr. Khan has been studying Health Sciences Centre. Recently his research
outbreaks of emerging and re-emerging has focused on COVID-19 specifically in the
diseases for more than a decade to lay the areas of diagnostics, and the development
scientific foundation for a global early warning and evaluation of vaccines and therapeutics.
system for infectious diseases. To translate
MEL KRAJDEN
and disseminate scientific knowledge into
Mel Krajden MD, FRCPC is the Medical Director
timely action, Dr. Khan founded BlueDot in
of the BC Centre for Disease Control Public
2013, a digital health company that combines
Health Laboratory and the Medical Head of
human and artificial intelligence to help
Hepatitis at the British Columbia Centre for
governments protect their citizens, hospitals
Disease Control. He is also a Professor of
protect their staff and patients, and businesses
Pathology and Laboratory Medicine at the
protect their employees and customers from
University of British Columbia. He currently a
dangerous infectious diseases. Dr. Khan
member of Federal COVID Immunity Task Force
recently received a Governor General’s Award
and facilitates the Testing Working Party. His
for his work transcending clinical medicine,
laboratory research involves the application of
public health, big data, and artificial intelligence.
molecular techniques to diagnose viruses,
IAN KITAI assess correlates between infection and
Ian Kitai is Tuberculosis Specialist at SickKids clinical disease, and track microbial infections
and first author of the paediatric chapter of for epidemiological purposes. His clinical
the Canadian TB standards, as well as many research involves integration of hepatitis
publications related to childhood TB. He has prevention and care services which involves the
worked in rural Zimbabwe with Oxfam UK use of linked laboratory and administrative
and in Norway House, Manitoba with the data to help understand how to measure
Northern Medical Unit of University of Manitoba. population level health outcomes for policy
He is a professor in the Department of making. He has extensive clinical trials expertise
Paediatrics at the University of Toronto. and has received CIHR funding in the fields of
human papillomavirus, HIV, hepatitis C virus
ROBERT KOZAK and COVID-19. He is also a Co-PI/Mentor for
Robert Kozak completed his PhD in microbiology
CIHR funded Canadian Hepatitis C Network
and immunology at McGill University. Following
(CanHepC) and has >300 publications.
this he completed post-doctoral fellowships
in viral hepatitis and zoonotic viruses at McGIll JOANNE LANGLEY
and the Ontario Veterinary College, University Joanne Langley is a Professor of Pediatrics
of Guelph, respectively. Before entering the and Community Health and Epidemiology at
clinical microbiology training program at the Dalhousie University and the Canadian Center
University of Toronto, he trained at the for Vaccinology in Halifax, NS Canada, head of
Special Pathogens Program at the National Pediatric Infectious Diseases at the IWK
Microbiology Laboratory in Winnipeg where Health Centre, and lead for the Clinical Trials
he studied viral hemorrhagic fevers, and Network of the Canadian Immunization
zoonotic viruses. During this time, he led Research Network. She currently co-chairs
teams investigating Ebola virus transmission the Canadian COVID-19 Vaccine Task Force.
in animals models and developing vaccines Her research is focused on the epidemiology
and countermeasures for Crimean Congo and vaccine prevention of respiratory infections,
Hemorrhagic fever virus. Additionally, he was particularly Respiratory Syncytial Virus and
involved in projects investigating Middle East influenza, and immunization decision making.
Respiratory Syndrome coronavirus, hantavirus
Speaker Biographies | 23You can also read
